ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 935,13
-0,62%
Dow Jones
37 903,29
0,00%
DAX
17 954,86
0,18%
Brent Oil
83,915
0,45%
Bitcoin
58 822,87
1,00%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kura Oncology Inc (KURA)

  7. Kura Oncology Inc (KURA) Actualités

KURA Kura Oncology Inc

20,28
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:59:41
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Kura Oncology Inc KURA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 20,28 13:59:41
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
20,28
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202413:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22/4/202413:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10/4/202413:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05/4/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06/3/202413:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
01/3/202423:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
27/2/202422:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:03EDGAR2Form 8-K - Current report
27/2/202422:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26/2/202413:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22/2/202413:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20/2/202413:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
15/2/202422:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202423:58EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202423:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202423:21EDGAR2Form S-3 - Registration statement under Securities Act of..
02/2/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
31/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202422:10EDGAR2Form 144 - Report of proposed sale of securities
30/1/202413:08EDGAR2Form 8-K - Current report
30/1/202413:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
26/1/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202422:08EDGAR2Form 8-K - Current report
24/1/202422:12EDGAR2Form 144 - Report of proposed sale of securities
24/1/202413:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
04/1/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202315:01EDGAR2Form 8-K - Current report
11/12/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202313:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..
28/11/202313:30GLOBEKura Oncology to Participate in the JMP Securities..
02/11/202321:39EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:03EDGAR2Form 8-K - Current report
02/11/202321:01GLOBEKura Oncology Reports Third Quarter 2023 Financial Results
02/11/202312:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
30/10/202312:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
26/10/202322:05GLOBEKura Oncology to Report Third Quarter 2023 Financial Results
19/10/202313:30GLOBEKura Oncology Announces First Patient Dosed in FIT-001 Trial..
17/10/202322:05GLOBEKura Oncology Announces Positive Results from..
04/10/202313:30GLOBEKura Oncology Announces Three Presentations at..
28/9/202313:30GLOBEKura Oncology Reports Preclinical Data Showing Ability of..
19/9/202313:30GLOBEKura Oncology to Participate in Cantor Global Healthcare..

Dernières Valeurs Consultées

NASDAQ
KURA
Kura Oncology
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés